Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Keeps Halo Pharma to drive independent growth
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system
Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Subscribe To Our Newsletter & Stay Updated
